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Apigenin, a natural plant ﬂavonoid with antiproliferative activity, is emerging as a promising compound for cancer prevention
and therapy, but its mechanism of action remains unclear. High expression of the small heat-shock protein-27 (Hsp27) in
leukemia contributes to the resistance of these cells to cancer treatments. Changes in Hsp27 phosphorylation have been
associatedwithheatandmetabolicstress,butitsroleinﬂavonoidanticanceractivityhasnotbeeninvestigated.Inthisstudy,we
examined the effect of apigenin in the regulation of Hsp27 on leukemia. We showed that apigenin does not affect Hsp27
expression but induces a bimodal phosphorylation on Ser78 and Ser82. The phosphorylation at early times was regulated by
p38. At later times, Hsp27 phosphorylation was dependent on p38 activity and for some residues on PKCd. Silencing of p38
expression reduced apigenin-induced phosphorylation on Ser15, Ser78, and Ser82, whereas silencing of PKCd expression
reduced the phosphorylation on Ser15 and Ser82 without affecting Ser78. In addition, we found that apigenin-induced PKCd
activity is mediated by p38. We also showed that the phosphorylation of Hsp27 signiﬁcantly increased the susceptibility
of leukemia cells to apigenin-induced apoptosis. Together, these results identify a complex signaling network regulating the
cytotoxic effect of apigenin through Hsp27 phosphorylation.
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Flavonoids have long been recognized as having potential
anticancer, anti-inﬂammatory, antioxidant, and antimicrobial
properties, serving as important nutraceutical components
of our diet.
1–4 Apigenin (40,5,7-trihydroxyﬂavone), a common
plant dietary ﬂavonoid found at high levels in parsley and
celery, abundant vegetables in the Mediterranean’s diet,
5
is emerging as an alternative anticancer compound, but its
mechanism of action remains unclear. Apigenin induces
apoptosis with effectiveness in leukemia cells but to a lesser
extent on other cancer cells.
6–10 Moreover, apigenin showed
no antiproliferative effect in normal cells, suggesting its
potential relevance as an anticancer compound.
9
Heat-shock proteins-27 (Hsp27) belongs to the conserved
family of small heat-shock protein chaperones.
11 Hsp27
associates with components of the extrinsic and intrinsic
apoptotic pathways, inhibiting the execution of the apoptosis
and is emerging as an antiapoptotic factor.
12–15 Elevated
expression of Hsp27 contributes to an increase in tumor-
igenicity and resistance to chemotherapy characteristic
of malignant cells.
16 In leukemia, high Hsp27 expression is
associated with adverse prognosis.
17 Changes on Hsp27
phosphorylation have been associated with heat and oxida-
tive stresses.
11,18–20 Phosphorylation of Hsp27 modulates
its oligomerization properties, thus probably modulating
Hsp27-cytoprotective activity.
21–23 Hsp27 is most commonly
phosphorylated in vivo as a result of stress conditions on
Ser15, Ser78, and Ser82 (referred in the text as S15, S78,
and S82,
24,25). Aberrant Hsp27 phosphorylation has been
linked to several clinical conditions. Hsp27 is phosphorylated
mainly through mitogen-activated protein kinase-activated
protein kinases (MKK2/3) as a result of the activation of the
mitogen-activated protein kinase p38 (p38).
24,25 In addition,
protein kinase Cd (PKCd) can phosphorylate Hsp27.
26,27
Also, the extracellular signal-regulated kinases (ERK1/2,
referred as ERK) became activated through PKCd regulating
MKK2/3 activity.
28,29 However, the effect of dietary apigenin
on Hsp27 has not been addressed.
In this study, we investigated the regulation of Hsp27 by
apigenin in leukemia cells. We found a bimodal phosphoryla-
tion of Hsp27 induced by apigenin. Using pharmacological
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www.nature.com/cddisinhibitors and siRNA, we found that apigenin induces an
‘early’ p38-dependent phosphorylation on S78 and S82.
A ‘late’ phosphorylation on S15, S78, and S82 is regulated
by notably different mechanisms. S15 and S82 phosphoryla-
tionisregulatedinap38/PKCdmanner.However,phosphory-
lation on S78 is regulated by p38 but is PKCd independent.
In addition, both ‘early’ and ‘late’ apigenin-induced Hsp27
phosphorylation events are ERK independent. We deter-
mined, using phosphor-mimic mutants, that Hsp27 phosphory-
lation signiﬁcantly increased the susceptibility of leukemia
cells to apigenin-induced apoptosis. These ﬁndings establish
that apigenin induces changes in Hsp27 phosphorylation
contributing to the cytotoxic activity of the ﬂavonoid.
Results
Apigenin increases Hsp27 phosphorylation. Apigenin
induces apoptosis in leukemia cells more effectively than in
other cells including, among others, lung or breast epithelial
cells and has no effect in normal ﬁbroblast, but the basis of
this difference remains unknown.
9 We previously showed
that Hsp27 is highly and constitutively expressed in mono-
cytic leukemia cells.
15 Moreover, high expression of Hsp27
has been correlated with chemoresistance. To determine the
effect of apigenin in Hsp27, THP-1 cells were treated with
50mM apigenin, an amount shown to induce apoptosis.
9 We
found that apigenin had no effect on the total expression
level of Hsp27 (Figure 1a, Hsp27). However, western blot
analysis using antibodies that recognize speciﬁcally Hsp27-
phosphorylated residues S15, S78, or S82 (Hsp27-pS15,
Hsp27-pS78, and Hsp27-pS82, respectively) showed that
apigenin induced a rapid and transient phosphorylation on
S78 and S82 after 15min, referred through out the text as
‘early’ phosphorylation (Figure 1a). This phosphorylation was
followed by a later increase observed at 6h on S15, S78, and
S82, named ‘late’ phosphorylation (Figure 1a).
Asphosphorylation of Hsp27is regulatedduring heat shock
by MAPKs, we next investigated the effect of apigenin on p38
and ERK. We found that after 15min apigenin induced
the transient phosphorylation of p38, followed by a second
increase in phosphorylation at 6h that remained high even at
9h (Figure 1b. p-p38). In addition, ERK phosphorylation
increased after 3h, reaching its maximum at approximately
6h (Figure 1b, p-ERK).
As Hsp27 phosphorylation can be regulated by PKCd in
other stress conditions, we next determined the effect of
apigenin on the activity of PKCd. For this purpose, lysates
from THP-1 cells treated with 50mM apigenin for different
times were immunoprecipitated with anti-PKCd antibodies,
or with an isotype control, and the immunoprecipitates were
subjected to in vitro kinase assays using histone 2B (H2B) as
exogenous substrate. We found that PKCd activity increased
at 6h (Figure 1c, H2B).
These results show that apigenin had no effect on the
expression level of Hsp27 but did induced changes in Hsp27
phosphorylation. Apigenin induced a rapid and steady
activation of p38 that coincides with the ‘early’ phosphoryla-
tionofHsp27anda‘late’phosphorylationofHsp27concurrent
to the activation of ERK and PKCd.
Differential regulation of early and late Hsp27
phosphorylation. Because apigenin induced the activation
of p38 at 15min, a time that coincides with the ‘early’
phosphorylation of Hsp27, we investigated whether p38
was involved in the regulation of Hsp27 phosphorylation in
apigenin-treated cells. THP-1 cells were pretreated for 1h
with the p38 inhibitor SB203580 or with diluent ( ) before the
addition of apigenin for 15min. We found that the ‘early’
phosphorylation of Hsp27 at S78 and S82 induced by
apigenin was inhibited in cells pretreated with the p38
inhibitor (Figure 2, lane 3 versus 2, Hsp27-pS78 and
Hsp27-pS82). The ‘early’ phosphorylation observed was
induced by apigenin, as cells treated with diluent for 15min
or the p38 inhibitor and diluent showed just a basal signal
(Figure 2, lanes 1 and 4, respectively). These results suggest
that p38 regulates the ‘early’ phosphorylation of Hsp27
at both S78 and S82.
To delineate the signaling pathway involved in the ‘late’
phosphorylation of Hsp27, we ﬁrst studied the effect of ERK.
Figure 1 Apigenin induces phosphorylation of Hsp27 and activation of p38
and ERK-MAPK and PKCd. Lysates from THP-1 cells treated with 50mM apigenin
for different lengths of time were analyzed by immunobloting with (a) anti-phospho-
Hsp27-pS78, anti-phospho-Hsp27-pS82, anti-phospho-Hsp27-pS15, anti-total-
Hsp27, and anti-Tubulin antibodies. (b) Immunoblots with anti-phospho-p38, anti-
phospho-ERK, anti-total-p38, anti-total-ERK, and anti-b-Tubulin antibodies.
(c) PKCd kinase activity was determined by in vitro kinase assays. Total cell
lysates were immunoprecipitated (IP) with anti-PKCd antibodies or an isotype
control (IgG) followed by in vitro kinase assay in the presence of (g-
32P)ATP and
H2B as substrate. Phosphorylated kinase products were resolved by SDS-PAGE
and transferred to a nitrocellulose membrane. Phospholabeled proteins were
visualized by autoradiography. Immunoblots of the same membrane with PKCd
served as loading control. Results are a representative of four independent
experiments
Effect of apigenin in the regulation of Hsp27 on leukemia
ME Gonzalez-Mejia et al
2
Cell Death and DiseaseTHP-1 cells were pretreated with diluent control or the ERK
inhibitor PD98059 for 1h before the addition of 50mM
apigenin. Treatment with the ERK inhibitor had no effect on
apigenin-induced phosphorylation of Hsp27 (Figure 3, lane 3
versus 2), and cells treated with the inhibitor or diluent alone
showed no phosphorylation of Hsp27 (Figure 3, lane 4 and 1).
In addition, the presence of the ERK inhibitor had no effect on
the phosphorylation of p38 induced by apigenin but inhibited,
as expected, the phosphorylation of ERK (Figure 3).
Next, we investigated the role of p38 and PKCd on the
‘late’ Hsp27 phosphorylation using pharmacological inhibi-
tors. THP-1 cells were pretreated with the p38 inhibitor
SB203580, or the PKCd inhibitor rottlerin, or both inhibitors, or
with diluent for 1h before the addition of 50mM apigenin for
6h. We found that apigenin-induced phosphorylation of S78
was signiﬁcantly inhibited in the presence of the p38 inhibitor
SB203580 (Figure 4a, lane 3 versus 2, **Po0.001), reaching
levels similar to that in control cells (Figure 4a, lane 3 versus 1).
In contrast, the PKCd inhibitor rottlerin had no effect on the
phosphorylation of S78 (Figure 4a, lane 4 versus 2, NS¼non-
statistically signiﬁcant). Addition of both SB203580 and
rottlerin showed decreased S78 phosphorylation to levels
similarly observed in the presence of the p38 inhibitor alone
(Figure4a, lane 5 versus3).However, wefound noadditive or
synergistic effects when cells were treated with both inhibitors
simultaneously (Figure 4a, lane 5 versus 2, **Po0.001). The
phosphorylation of S82 induced by apigenin was signiﬁcantly
inhibited by pretreatment with the p38 inhibitor SB203580
(Figure 4b, lane 3 versus 2, *Po0.05). In contrast to the lack
of effect observed on S78, the PKCd inhibitor rottlerin,
signiﬁcantly inhibited apigenin-induced phosphorylation
of S82 (Figure 4b, lane 4 versus 2, *Po0.05). Similar to S82
phosphorylation, we observed that the pretreatment with
the p38 inhibitor SB203580 inhibited apigenin-induced phos-
phorylation of S15 (Figure 4c, lane 3 versus 2, *Po0.05).
In addition, rottlerin decreased apigenin-induced phosphor-
ylation of S15 (Figure 4c, lane 4 versus 2, *Po0.05).
The addition of both inhibitors, however, showed no additive
or synergistic effects (Figure 4c, lanes 5, 4 versus 2,
**Po0.001).
To further study the signaling network responsible for
apigenin-induced Hsp27 phosphorylation and to take into
consideration the possible limitation of speciﬁcity of kinase
inhibitors, we next assessed the effect of silencing p38 and
PKCd,respectively. THP-1 cellswere transfectedwith siRNA-
p38 or siRNA-Control, and the phosphorylation status of
Hsp27 was evaluated after treatment with 50mM of apigenin
or diluent for 6h. We found that silencing of p38 signiﬁcantly
decreased apigenin-induced phosphorylation of S15, S78,
and S82 (Figure 5a, lane 6 versus 4), whereas apigenin-
induced phosphorylation of Hsp27 remained similarly ele-
vated in cells transfected with siRNA-Control or in non-
transfected (Figure 5a, lane 4 versus 2). Silencing of PKCd
decreased phosphorylation of S15 and S82, but had no effect
on apigenin-induced phosphorylation of S78 (Figure 5b, lane
6 versus 4). These results suggest that the ‘late’ phosphor-
ylation of Hsp27 is regulated by different signaling networks
Figure 2 Apigenin-induced ‘early’ Hsp27 phosphorylation is dependent on p38
activity. Lysates from THP-1 cells treated with the diluent alone (lane 1), pretreated
with 10mM p38 inhibitor SB203580 or diluent (lanes 3 and 2) before the addition
of 50mM apigenin for 15min following or treated with the p38 inhibitor SB203580,
and diluent (lane 4) were immunoblotted with anti-phospho-Hsp27-pS78, anti-
phospho-Hsp27-pS82, anti-phospho-p38, anti-total-Hsp27, anti-total-p38 anti-
bodies. The same membrane was immunoblotted with anti-Tubulin antibodies
as loading control. Results are a representative of four independent experiments
Figure 3 Apigenin-induced ‘late’ Hsp27 phosphorylation is ERK-independent.
LysatesfromTHP-1cellsweretreatedwithdiluent(lane1),orpretreatedwithdiluent
or 25mM PD98059 before the addition of 50mM apigenin for 6h (lanes 2 and 3,
respectively) and immunoblotted with anti-phospho-Hsp27-pS78, anti-phospho-
Hsp27-pS82, anti-phospho-Hsp27-pS15, anti-phospho-ERK, anti-total-Hsp27,
anti-total-ERK antibodies. The same membrane was immunoblotted with anti-
b-Tubulin antibodies as loading control. Results are a representative of four
independent experiments
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Cell Death and Diseasedependingon theamino-acid residue; S78isregulatedbyp38
whilephosphorylationofS15andS82ismediatedbybothp38
and PKCd.
PKCd activity is modulated by p38. As both PKCd and p38
regulate the ‘late’ phosphorylation of Hsp27, we next studied
the relationship of these kinases in the pathway. As shown in
Figure 6a, cells treated with apigenin for 6h have elevated
levels of phosphorylated p38 when compared with cells
treated with diluent (Figure 6a, lane 2 versus 1). We found
that pretreatment with the PKCd inhibitor rottlerin before the
addition of apigenin had no effect on the phosphorylation
status of p38 (Figure 6a, lane 4 versus 2), whereas
SB203580 inhibited apigenin-induced phosphorylation of
p38 (Figure 6a, lane 3 versus 2). Next, we determined the
effect of inhibiting p38 on the apigenin-induced activity of
PKCd. For this purpose, lysates from THP-1 cells pretreated
with the p38 inhibitor SB203580 or diluent and followed by
6h of treatment with 50mM apigenin were immunopreci-
pitated with anti-PKCd antibodies. Immunoprecipitates were
subjected to in vitro kinase assays using H2B as exogenous
substrate. We found that apigenin-induced PKCd activity was
decreased in cells treated with the p38 inhibitor (Figure 6b,
lane 4 versus 3). This effect was similar to the inhibition
observed in cells treated with apigenin in the presence of the
PKCd inhibitor rottlerin (Figure 6b, lane 5 versus 4). A similar
decrease in PKCd activity was found in cells treated with
apigenin in the presence of both SB203580 and rottlerin
(Figure 6b, lane 6 versus lanes 4 and 5).
To further evaluate whether the activity of PKCd was
dependent on p38, we assessed PKCd activity in THP-1 cells
transfected with siRNA-p38 or siRNA-Control. Lysates from
cells transfected with siRNA-p38 or siRNA-Control and
treated with 50mM apigenin for 6h were immunoprecipitated
with anti-PKCd antibodies or an isotype control. Immunopre-
cipitates were subjected to in vitro kinase assays in
the presence of H2B as exogenous substrate. We found
reduced PKCd activity in siRNA-p38 lysates (Figure 6c, lane 2
versus 1). These results suggest that p38 regulates PKCd in
the signal cascade induced by apigenin.
Phosphorylation of Hsp27 modulates apigenin-induced
apoptosis. Phosphorylation of Hsp27 has been shown to
modulate its protective activity against stress conditions.
23
To assess whether the phosphorylation of Hsp27 affects
apigenin-induced apoptosis, we examined the effect of
phosphor-mimic mutants, in which all three S15, S78, and
S82 were mutated to aspartic acids, Hsp27-D, or to alanines,
Hsp27-A.
23 Lysates from THP-1 cells transfected with
an empty vector or either Hsp27 wild-type (Hsp27-WT),
Figure 4 ‘Late’ Hsp27 phosphorylation induced by apigenin is modulated by p38-MAPK and PKCd. Lysates from THP-1 cells treated with 50mM apigenin for 6h and
diluent or following 1h pretreatment with 10mM SB203580, 15mM rottlerin, or both. Treatments marked with ( ) denote addition of diluent. (a) Immunoblots with
anti-phospho-Hsp27-pS78 and anti-total-Hsp27 antibodies. (b) Immunoblots with anti-phospho-Hsp27-pS82 and anti-total-Hsp27 antibodies. (c) Immunoblots with anti-
phospho-Hsp27-pS15 and anti-total-Hsp27 antibodies. Densitometry data normalized by the loading control are represented as mean±S.E.M. (N¼5, *Pp0.05 and
**Pp0.001, NS denotes non-statistical signiﬁcance)
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Cell Death and DiseaseHsp27-A, or Hsp27-D were used to assess the expression of
Hsp27-WT and the Hsp27 phosphor-mutants. Immunoblot
analysis using the anti-Myc antibodies showed equal
expression of Hsp27-WT, Hsp27-A, and Hsp27-D mutants
(Figure 7a). Next, the cells were treated with diluent for 9h
(referred as NT) or treated with 50mM apigenin for 6 or 9h,
times when Hsp27 phosphorylation was observed. In cells
transfected with the empty vector, we found that apigenin
induced 20% apoptosis by 9h as determined by AnnexinV/7-
AAD staining (Figure 7a). This percentage of apoptosis was
similar to numbers reported in non-transfected cells treated
for 9h with apigenin.
9 Overexpression of Hsp27-WT reduced
by half the percentage of cells undergoing apoptosis at 9h
(Figure 7a). Similar results were obtained in cells expressing
the Hsp27-A mutant (Figure 7a). In contrast, overexpression
of Hsp27-D signiﬁcantly increased the number of apoptotic
cells after 9h of apigenin treatment, reaching levels similar to
the number of apoptotic cells found in cells transfected with
the vector control (Figure 7a). Similarly, we found that
overexpression of Hsp27-WT or Hsp27-A signiﬁcantly
decreased the percentage of active caspase-3-positive
cells at 9h (Figure 7b), whereas Hsp27-D overexpressing
cells showed a signiﬁcant increase of apoptosis compared
with Hsp27-WT or the Hsp27-A mutant (Figure 7b). Next,
lysates from the same cells were used to determine the
Figure 5 PKCd and p38-MAPK regulate the ‘late’ phosphorylation of Hsp27
induced by apigenin. Silencing of p38 and PKCd inhibits apigenin-induced-Hsp27
phosphorylation. (a) Immunoblots of lysates from THP-1 cells non-transfected (NT)
or transfected with siRNA-Control or siRNA-p38 were treated with diluent ( )o r
treated for 6h with 50mM apigenin (þ). (b) Immunoblots of lysates from THP-1
cells non-transfected (NT) or transfected with siRNA-Control or siRNA-PKCd and
treated with diluent ( ) or treated for 6h with 50mM apigenin (þ). Results are a
representative of three independent experiments
Figure 6 p38-MAPK modulates apigenin-induced PKCd activity. THP-1 cells
treated with 50mM apigenin for 6h alone or following 1h pretreatment with 10mM
SB203580, a p38 inhibitor, 15mM rottlerin, a PKCd inhibitor, or both, and lanes
marked with ( ), denote addition of diluent, were (a) immunobloted with anti-
phospho-p38, anti-total-p38, and anti-b-Tubulin antibodies. (b) Lysates were
immunoprecipitated (IP) with anti-PKCd antibodies or an isotype control (IgG),
followed by in vitro kinase assay in the presence of (g-
32P)ATP and H2B as a
substrate. Kinase products were resolved by SDS-PAGE and transferred to a
nitrocellulose membrane. Phospholabeled proteins were visualized by autoradio-
graphy. The same membrane was immunoblotted with anti-PKCd antibodies
as loading control. (c) Lysates from THP-1 cells transfected with siRNA-Control
or siRNA-p38were treatedfor 6h with 50mM apigeninandimmunoprecipitated(IP)
with anti-PKCd antibodies or an isotype control (IgG), followed by in vitro kinase
assayin the presenceof (g-
32P)ATPandH2B as a substrate.Kinaseproducts were
resolved by SDS-PAGE and transferred to a nitrocellulose membrane.
Phospholabeledproteinswerevisualizedbyautoradiography.Thesamemembrane
was immunoblotted with anti-PKCd antibodies as loading control. Results are a
representative of three independent experiments
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Cell Death and Diseasecaspase-3 activity by the DEVD-AFC activity assay. We
found that cells transfected with vector control and treated
with apigenin for 6 or 9h showed increased caspase-3
activity compared with cells treated with diluent (Figure 7c,
treated with diluent, referred as NT). Cells expressing Hsp27-
WT or Hsp27-A have decreased caspase-3 activity at 9h
compared with cells transfected with the vector control and
treated with apigenin for a similar time. In contrast, cells
expressing Hsp27-D showed high caspase-3 activity at 9h,
reaching levels of caspase-3 similar to the cells transfected
with the vector control (Figure 7c). Thus, expression of the
phosphor-mimic mutant Hsp27-D increases caspase-3
activity. To further assess the effect of the Hsp27
phosphorylation in apoptosis, we evaluated the effect of the
Hsp27 phosphor-mimic mutants in the cleavage of caspase-
3 during the treatment with apigenin. We found that cells
expressing Hsp27-WT or Hsp27-A and treated for different
times with 50mM apigenin had reduced levels of cleaved
caspase-3 and more full-length caspase-3 after 9h of
treatment compared with cells transfected with the vector
control (Figure 7d). In contrast, cells expressing Hsp27-D
showed increased levels of cleaved caspase-3 and
reduced levels of full-length caspase-3 compared with cells
expressing either Hsp27-WT or Hsp27-A (Figure 7d). These
ﬁndings are consistent with the increase in percentage of
apoptotic cells, increase in number of cells with active
caspase-3, and increase in caspase-3 activity, obtained by
other currently well-accepted methods to determine
apoptosis (Figure 7a–c). Collectively, these results suggest
that Hsp27 phosphorylation regulates apigenin-induced
apoptosis.
Discussion
Dietary ﬂavonoids are emerging as alternative anticancer
agents. Apigenin, a ﬂavonoid abundantly found in fruits and
vegetables, induces cell death with variable but relatively low
efﬁcacy, in human colon carcinoma, breast cancer, and
prostate cancer.
6,7 Despite its low efﬁcacy in epithelial cells
apigenin induces apoptosis with high efﬁcacy in myelogenous
Figure 7 Hsp27 phosphorylation increases apigenin-induced apoptosis. THP-1
cells transiently transfected with empty vector or Hsp27-WT, Hsp27-A, or Hsp27-D
were treated with diluent control for 9h (NT) or with 50mM apigenin for different
times. (a) Percentage of apoptotic cells was determined by Annexin V/7-AAD
staining. (b) Active caspase-3 was determined in the same cells by FACS.
(c) Lysates from cells obtained in (a) were used to determine caspase-3 activity by
theDEVD-AFCassay.(d)Lysatesfromcellsobtainedin(a)wereusedtodetermine
inactive full-length (FL-casp-3) and cleaved caspase-3 (cleaved casp-3)
by immunoblotting. Values shown in (a), (b), and (c) represent mean±S.E.M.,
N¼4, *Pp0.01
Figure 8 Working model of regulation of Hsp27 phosphorylation during
apigenin-induced apoptosis
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Cell Death and Diseaseleukemia cells.
8,9 However, the mechanisms regulating
apigenin-induced apoptosis in leukemia cells remain elusive.
Leukemia cells express constitutively high levels of
Hsp27,
12,15 and overexpression of Hsp27 was shown to
confer resistance to chemotherapeutic drugs.
30 Heat or other
stresses induce changes in Hsp27 phosphorylation.
20,23,31
Phosphorylation of Hsp27 was found to affect its oligomeriza-
tionstatebydecreasingHsp27chaperoneactivity.
20,21,23,32,33
In addition, changes in Hsp27 phosphorylation were sugg-
ested to modulate Hsp27 cytoprotective activity by probably
modulating its interaction with other molecules.
22,34 Here, we
investigated the effect of apigenin in the regulation of Hsp27
and its role in apoptosis.
Our results demonstrated that apigenin had no effect on the
total expression level of Hsp27. However, apigenin induced a
distinct bimodal phosphorylation of Hsp27, differentially
regulated depending on the amino-acid residue, which
modulates apigenin-induced apoptosis. Under stress condi-
tionsandheat shock, Hsp27isphosphorylatedin vivoon S15,
S78, and S82 through a signal kinase cascade regulated by
p38 and PKCd.
20,23,26 We found that apigenin induced unique
bimodal kinetics of Hsp27 phosphorylation (Figure 8). An
‘early’ phosphorylation of Hsp27 after 15min of treatment
with apigenin was only observed on S78 and S82 and
was regulated by the p38-MAPK (Figures 1 and 2). This
‘early’ phosphorylation of Hsp27 precedes the activation of
caspase-3 and ROS production, two events we previously
reported, and further studies will need to be conducted to
investigate the role of the ‘early’ phosphorylation. Using
pharmacological inhibitors and silencing experiments, we
found that Hsp27 is phosphorylated on the three residues,
S15, S78, and S82, after treatment with apigenin for 6h
(Figures 1, 4 and 5). We referred to this phosphorylation as
‘late’ phosphorylation (Figure 8). Notably, these results
indicate a different signaling network that seems to regulate
the phosphorylation of these three amino-acid residues.
Phosphorylation of S78 was p38 dependent, whereas
phosphorylation of S15 and S82 was regulated by p38 and
PKCd (Figure 8). We cannot rule out the possibility that p38
could regulate S15 and S82 phosphorylation but with a
competitive disadvantage to that of PKCd and, if so, only
regulate the phosphorylation of these residues directly in the
absence of PKCd activity (Figure 8). Unlike Hsp27 phosphor-
ylation induced by oxidative stress,
35 we found that the
phosphorylation of Hsp27 induced by apigenin was indepen-
dent of ERK (Figure 3). During heat and metabolic stresses,
the main Hsp27 sites phosphorylated in vivo were S78 and
S82.
24FindingsbyGaestelandcoworkers,however,reported
that incorporation on S15, while 10 times lower, was also
observed upon stimulation.
23 Phosphorylation of Hsp27 is
catalyzed directly by the MKK2/3 through p38 activation
during different stress conditions.
34 Upon activation of p38,
Hsp25, the Hsp27 mouse homolog, can also be phosphory-
lated by PKCd.
26 Unlike radiation-induced Hsp27 phosphor-
ylation, where PKCd is upstream of p38,
36 we found that the
activation of PKCd induced by apigenin was mediated by p38
(Figures 6 and 7).
The bimodal Hsp27 phosphorylation kinetics observed in
leukemia cells treated with apigenin is so far unique
and suggests a complex regulatory network responsible of
Hsp27 regulation (Figure 8). Although the biological effect
of the ‘early’ Hsp27 phosphorylation will need further studies,
we found that the ‘late’ phosphorylation of Hsp27 regulates
apigenin-induced apoptosis. The expression of phosphor-
mimic Hsp27-D mutant was shown previously to regulate
Hsp27 oligomerization state but failed to protect cells against
oxidative stress.
23 We found that overexpression of the same
phosphor-mimic mutant Hsp27-D rendered leukemia cells
more susceptibletoapigenin-inducedapoptosisbyincreasing
the percentage of apoptotic cells after 9h, as determined
by AnnexinV/7-AAD, active caspase-3 staining, caspase-3
activity, and the proteolytic cleavage of caspase-3 (Figure 7).
Collectively, our studies identify a complex signaling kinase
networkinvolved inHsp27phosphorylationinduced byapigenin
and provide novel insights into the molecular mechanism
responsible for the anticancer activity of this ﬂavonoid.
Materials and Methods
Cell culture and reagents. THP-1 cells were obtained from the ATCC and
cultured in RPMI 1640 medium with L-glutamine (BioWhittaker, Walkersville, MD,
USA) supplemented with 5% FBS (Atlas Biological, Lawrenceville, GA, USA), 1%
penicillin–streptomycin (Lonza, Walkersville, MD, USA) and at a density lower than
0.5 10
6cells/ml. All cells were grown at 371C in a humidiﬁed atmosphere of 95%
air and 5% CO2. Apigenin (A-Apin Chemicals, Oxon, UK), the PKCd inhibitor
rottlerin and the diluent dimethyl sulfoxide (DMSO) were obtained from Sigma-
Aldrich (St Louis, MO, USA). In all the experiments, cells were treated with 50mM
apigenin. The p38 inhibitor SB203580, the ERK inhibitor PD98059 (Calbiochem,
San Diego, CA, USA), and rottlerin were dissolved in DMSO and added to the cell
culture 1h before the addition of apigenin at 10, 25, and 15mM, respectively.
Extract preparation and western blot analysis. Cells were collected
by centrifugation, washed with PBS and lysed for 1h at 41C with continuous
vortexing in ice-cold buffer B (50mM HEPES pH 7.4, 2.5mM EGTA, 1mM EDTA,
150mMNaCl,10%glycerol,0.1%Tween-20containingthephosphataseinhibitors:
20mM NaF, 10mM Na glycerophosphate, 5mM Na pyrophosphate, 1mM
orthovanadate, 1mM DTT, 0.1mM PMSF, 2mg/ml of protease inhibitors:
chymostatin, pepstatin, leupeptin, antipain). Extracts were then centrifuged for
5min at 14000r.p.m. at 41C. Laemmli buffer containing 2.5% b-mercaptoethanol
(BioRad,Hercules,CA,USA)wasaddeddirectlytothecelllysates,andthesamples
were boiled for 5min before loading onto gels. Equal amounts of protein were
loaded and separated by SDS-PAGE, transferred onto nitrocellulose membranes,
and probed with antibodies of interest followed by enhanced chemiluminescence
with secondary antibodies conjugated to horseradish peroxidase (Amersham
Biosciences, Arlington Heights, IL, USA). Phospho-Hsp27-pS15 (SPA-525),
phospho-Hsp27-pS78 (SPA-523), phospho-Hsp27-pS82 (SPA-524), and total Hsp27
(SPA-803) antibodies were obtained from Stressgen (British Columbia, Canada).
Antibodies used for MAPK, total p44/42 (referred as ERK in the text, cat. 9102),
phospho-ERK (9101), phospho-p38 (9211), and total p38 (9212) were from
Cell Signaling (Boston, MA, USA). PKCd (SC-937) antibody was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), anticleaved active caspase-3
antibodies (9661S, Clone Asp 175) were from Cell Signaling (Danvers, MA, USA)
anti-full-length inactive caspase-3 antibodies (610323) were from BD Biosciences
(San Jose, CA, USA) and b-Tubulin (05-661) was acquired from Millipore (Billerica,
MA, USA). Densitometry analysis was performed using Quantity One software
(BioRad), and data were normalized using the loading control b-Tubulin. For
Figure 4, the data representingthe densitometry analysis obtainedfrom theamount
of phospho-Hsp27 divided by the total amount of Hsp27 was represented as a
percentage of the amount found in non-treated cells.
Transient transfection, siRNA, and ﬂow cytometry. THP-1 cells
were transiently transfected using the Amaxa Nucleofector (Amaxa, Cologne,
Germany) program V-001 at a ﬁnal concentration of 1 10
7cells/ml in a 100ml
volume, as previously described.
15 Five micrograms of empty vector (pcDNA3-
5myc), vector containing Hsp27-WT, a Hsp27-phosphor-mutant in which S15, S78,
and S82 were replaced by Asp and is referred in the text as Hsp27-D or in which
S15,S78,andS82werereplacedbyAlaandisreferredasHsp27-A(agenerousgift
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23) were used for transfections. The transfection efﬁciency for the
clonesused,Hsp27-WT,Hsp27-D,andHsp27-A,was similarand averagedB50%
as determined by FACS analysis in cells stained with anti-Myc antibodies
(not shown), and is similar to the transfection efﬁciency previously reported by this
method.
15 Twenty-four hours after transfection, the cells were treated with 50mM
apigenin for the indicated times. For silencing experiments, THP-1 cells were
transfected with 50nM siRNA-p38 (Signal Silencing pool p38-MAPK siRNA; Cell
Signaling, Cat: 6386), siRNA scramble control (Qiagen, Valencia, CA, USA; Cat:
1027284) or 100nM siRNA-PKCd (Qiagen, Cat: 1027283 using the Amaxa
nucleofector program V-001 as previously described.
9 Cells were treated, as
described in the text, 48h after siRNA transfections. Apoptosis was assessed by
staining cells with AnnexinV/7-AAD using the Annexin V-FITC apoptosis detection
kit, following the manufacturer’s speciﬁcation (BD Biosciences). Alternatively, cells
were washed with PBS and resuspended at a concentration of 2 10
6cells/ml in
blocking buffer (PBS containing 1% FBS and 200mg/ml human total IgG) and
incubated for 30min on ice, washed twice with blocking buffer, resuspended in
250ml cytoﬁx/cytoperm, and incubated for 20min on ice with 20ml of FITC-
conjugated antiactive-caspase-3 antibodies (BD Pharmingen, San Jose, CA, USA).
Cells were rinsed twice with Perm/Wash buffer and resuspended in blocking buffer
for ﬂow analysis. Flow cytometry analysis was performed using Becton Dickinson
FACS Calibur (San Jose, CA, USA) using Cell Quest version 3.3 software as
previously described.
15
Immunoprecipitations and in vitro kinase assays. Fifty micrograms of
THP-1 lysates were immunoprecipitated overnight at 41C with 200ng of anti-PKCd
antibody (SC-937) or IgG isotype as control (SC-2027), followed by 1h incubation
with 25ml of protein G-agarose beads (Amersham Biosciences). Immuno-
precipitates were rinsed three times with buffer B and one time with kinase buffer
(25mMHEPESpH7.4,10mMMnCl2,1mMMgCl2,1mMDTT,0.1mMPMSF)and
subjected to in vitro kinase assays by incubating the beads for 1h at 371C in the
presence of 40ml of kinase assay buffer containing 2mCi of (g-
32P) ATP (Perkin
Elmer,Boston, MA,USA), 0.5mMATP,200mg/mlphosphatidyl-serine,and20mg/ml
diacylglycerol, in the presence of 1mg H2B (Roche Applied Science, Mannheim,
Germany) as exogenous substrate. All reactions were stopped by the addition of
Laemmli buffer, boiled for 5min and loaded onto SDS-PAGE.
Caspase-3 activity assay. Active caspase-3 was determined by the AFC
assay, as previously described.
37 Lysates were incubated in a cyto-buffer (10%
glycerol, 50mM Pipes, pH 7.0, 1mM EDTA, containing 1mM DTT) containing
20mM of the tetrapeptide substrate DEVD-AFC. The tetrapeptide was obtained
from Enzyme Systems Products (Livermore, CA, USA). Release of free AFC was
determinedusingaCytoﬂuor4000ﬂuorometer(PerseptiveCompany,Framingham,
MA, USA; Filters: excitation; 400nm, emission; 508nm).
Statistical analysis. All data are expressed as mean±S.E.M., and two way
Student’s t-test comparisons were used to assess statistical signiﬁcance. Statistical
signiﬁcance is stated in the text.
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